Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Jaguar Health Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
JAGX
Nasdaq
2834
https://jaguar.health/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Jaguar Health Inc
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
- Mar 27th, 2024 12:30 pm
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
- Mar 20th, 2024 12:30 pm
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
- Feb 23rd, 2024 1:30 pm
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
- Feb 15th, 2024 1:30 pm
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
- Feb 14th, 2024 1:30 pm
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
- Feb 12th, 2024 1:30 pm
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
- Jan 30th, 2024 1:45 pm
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
- Jan 29th, 2024 1:30 pm
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
- Jan 25th, 2024 1:30 pm
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jan 5th, 2024 9:15 pm
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
- Jan 4th, 2024 1:30 pm
11 Popular Penny Stocks on Robinhood
- Dec 24th, 2023 10:48 pm
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 61%
- Dec 18th, 2023 10:45 am
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
- Dec 11th, 2023 1:30 pm
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
- Dec 7th, 2023 1:30 pm
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
- Dec 6th, 2023 1:30 pm
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
- Dec 4th, 2023 1:30 pm
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
- Nov 30th, 2023 1:30 pm
Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
- Nov 21st, 2023 1:30 pm
Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2023 Earnings Call Transcript
- Nov 15th, 2023 6:14 pm
Scroll